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ARTICLE OPEN
Cognitive function in people with and without freezing
of gait in Parkinson’s disease
Rosie Morris1,2, Katrijn Smulders1,3, Daniel S. Peterson1,4,5, Martina Mancini 1, Patricia Carlson-Kuhta 1, John G. Nutt1 and
Fay B. Horak1,6✉
Freezing of gait (FOG) is common in people with Parkinson’s disease (PD) which is extremely debilitating. One hypothesis for the
cause of FOG episodes is impaired cognitive control, however, this is still in debate in the literature. We aimed to assess a
comprehensive range of cognitive tests in older adults and people with Parkinson’s with and without FOG and associate FOG
severity with cognitive performance. A total of 227 participants took part in the study which included 80 healthy older adults,
81 people with PD who did not have FOG and 66 people with PD and FOG. A comprehensive battery of neuropsychological
assessments tested cognitive domains of global cognition, executive function/attention, working memory, and visuospatial
function. The severity of FOG was assessed using the new FOG questionnaire and an objective FOG severity score. Cognitive
performance was compared between groups using an ANCOVA adjusting for age, gender, years of education and disease severity.
Correlations between cognitive performance and FOG severity were analyzed using partial correlations. Cognitive differences were
observed between older adults and PD for domains of global cognition, executive function/attention, and working memory.
Between those with and without FOG, there were differences for global cognition and executive function/attention, but these
differences disappeared when adjusting for covariates. There were no associations between FOG severity and cognitive
performance. This study identified no significant difference in cognition between those with and without FOG when adjusting for
covariates, particularly disease severity. This may demonstrate that complex rehabilitation programs may be undertaken in those
with FOG.
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INTRODUCTION
Freezing of gait (FOG) is one of the most problematic motor
symptoms in Parkinson’s disease (PD) affecting over 60% of
patients with a disease duration of 10 years or more1.
Furthermore, FOG contributes to an increased risk of falls, reduced
quality of life, increased mood disorders and increased caregiver
burden2–4. Not all patients with PD develop FOG. Incidence
increases with disease duration but clinically it is difficult to
predict which patients will transition to develop FOG. A number of
factors contribute to FOG risk which include age, anxiety,
depression, and severity of motor symptoms but the role of
cognition in the development of FOG is still debated in the
literature5–8.
Impaired cognitive function is common in PD, particularly for
frontal lobe functions of attention and executive function with
difficulties present at disease diagnosis9. A number of studies have
looked at differences in cognition between those with FOG (FOG+)
and without FOG (FOG−) suggesting that domains of executive
function, attention, and visuospatial function are worse in FOG+
compared to FOG−10–14. However, most studies to date are within
small cohorts and do not control for disease severity. The
association between cognitive decline and PD severity, and PD
severity and FOG is difficult to disentangle (Fig. 1). Therefore, it is
critical that disease severity is taken into account when comparing
cognitive function in those with and without FOG.
The severity of FOG is assessed in the majority of cases using
self-report questionnaires dependent on patient subjective
recall15,16. To better characterize and quantify FOG, an objective
measure may be better suited for assessment across participants
and when assessing relationships between FOG and behavioral
outcomes. Mancini et al., previously developed an objective
outcome measure of FOG that provides a continuous ratio score
validated against both the New FOG self-reported questionnaire
and expert neurologist evaluation17,18.
This study, therefore, aimed to: (i) assess a comprehensive range
of cognitive domains in a large cohort of older adults and PD
FOG+ and FOG− and (ii) associate cognitive performance with
FOG severity using subjective and objective FOG measures. We
hypothesize that those with PD will have poorer cognitive
function compared to older adults and specific to PD, measures
of executive function, attention, and visuospatial ability will be
worse in FOG+ compared to FOG−. In addition, PD participants
with more severe objective FOG scores will demonstrate poorer
attention, executive function and visuospatial abilities compared
to those with milder FOG.
RESULTS
Demographic and clinical assessments
A total of 227 participants were recruited to the study; 147 of
which were diagnosed with idiopathic PD and 80 healthy older
adults (OA). Of those with PD, 66 were classified as FOG+ and 81
were classified as FOG−. Demographic and clinical assessments
are shown in Table 1. When comparing OA and PD, there were no
differences for age or gender but those with PD had a poorer
MoCA score (OA; 26.87 ± 2.27, PD; 25.75 ± 3.40, p < 0.01). When
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comparing FOG+ and FOG−, there was no significant difference
for age, gender or MoCA (Table 1). However, motor disease
severity, as measured by the MDS-UPDRS III, was significantly
greater in the FOG+ group (45.92 ± 12.44) compared to the FOG−
group (36.20 ± 10.83, p < 0.001). The FOG+ group had significantly
greater FOG severity, as demonstrated by the FOG ratio score
(2.65 ± 6.03) compared to FOG− (0.68 ± 0.76, p < 0.01).
Cognitive performance between OA and PD and FOG+ and FOG−
Independent sample t-tests without covariates indicated that the
PD group had worse performance than the OA group for all
cognitive tests except for Go-NoGo (p= 0.02) and JoLO (p= 0.04),
see Table 2. Uncorrected, independent sample t-tests also showed
worse cognitive performance for the FoG+ compared to FoG− for
global cognition (SCOPA-COG, p < 0.01) and in the executive
function/attention domain for the Flankers test (p < 0.01), but no
other tests (see Table 2). Box and scatter plot representations of
cognitive assessments for OA, FOG−, and FOG+ are shown in Fig. 2.
Adjusting for age, gender and years of education, resulted in
fewer differences between PD and OA groups, with the PD group
exhibiting poorer global cognition (SCOPA-COG; p < 0.01), poorer
executive function/attention (SRT (p < 0.01), Stroop color (p < 0.01),
Stroop Interference (p < 0.01) and Flankers (p < 0.01) and poorer
working memory (Dot counting; p < 0.01) (Table 2). When
comparing FOG+ and FOG− and adjusting for age, gender, years
of education and disease severity (MDS-UPDRS III) there were no
significant differences between groups. To further understand the
effect of individual covariates, analyses were run controlling for
individual covariates (Supplementary Table 1) which revealed the
MDS-UPDRS III had the greatest effect on cognitive performance.
Association between FOG severity and cognitive performance
Cognitive performance was not correlated with either self-
reported FOG severity or objective FOG severity in any of the
groups (Table 3). The objective FOG ratio was weakly correlated
with the SCOPA-Cog in FOG+ (r=−0.28; p= 0.04), suggesting
Fig. 1 The association between disease severity, cognitive impairment and, freezing of gait (FOG). Disease severity directly impacts on
FOG and cognitive impairment. The indirect association between FOG and cognitive impairment remains unknown.
Table 1. Demographic and clinical characteristics for controls, PD and PD without freezing (FOG−) and PD with freezing (FOG+).
OA
(n= 80)
PD
(n= 147)
PD FOG−
(n= 81)
PD FOG+
(n= 66)
Independent T-test
OA vs PD FOG+ vs FOG−
Age (yrs) 68.21 (8.07) 68.48 (8.06) 68.80 (8.01) 68.08 (8.17) 0.814 0.589
Gender (M/F)a 48/32 95/52 50/31 45/21 0.490 0.416
Education (years) 16.61 (1.86) 16.23 (1.90) 16.20 (1.87) 16.26 (1.96) 0.150 0.841
MDS UPDRS-III N/A 40.56 (12.52) 36.20 (10.83) 45.92 (12.44) N/A <0.001
Disease duration (years) N/A 6.23 (4.93) 4.93 (4.19) 7.83 (5.31) N/A <0.001
MoCA 26.87 (2.27) 25.75 (3.40) 26.00 (3.05) 25.45 (3.80) <0.01 0.342
NFog Score N/A N/A N/A 12.00 (7.02) N/A N/A
FOG Ratio Score 0.41 (0.35) 1.55 (4.16) 0.68 (0.76) 2.65 (6.03) <0.01 <0.01
H&Ya 1 N/A 1 (0.7%) 1 (1.2%) 0 (0%) N/A <0.01
2 N/A 117 (79.6%) 72 (88.9%) 45 (68.2%)
3 N/A 16 (10.9%) 5 (6.2%) 11 (16.7%)
4 N/A 13 (8.8%) 3 (3.7%) 10 (15.2%)
aChi-squared test.
R. Morris et al.
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those with poorer global cognition had greater freezing severity,
but this did not reach the stringent significance level adjusted for
multiple comparisons (Fig. 3).
DISCUSSION
This large study compared a comprehensive range of neuropsy-
chological assessments in older adults and people with Parkin-
son’s disease, with and without freezing of gait. Although the
FOG+ group showed poorer executive and global cognitive
function compared to the FOG− group, this difference was not
significant when controlling for covariates, particularly disease
severity. As supported by previous work, this suggests that
cognitive deficits and FOG incidence may occur concomitantly as
PD progresses. In addition, we observed no associations between
FOG severity and cognitive impairment when using subjective or
objective measures of FOG severity, suggesting that severity of
FOG may not relate to severity of cognitive impairment.
Patients with PD demonstrate cognitive deficits, even in early
disease9, and our analysis demonstrates established cognitive
Table 2. ANCOVA for cognitive differences between FOG+ and FOG−.
Cognitive Domain Control
(n= 80)
PD
(n= 147)
PD FOG−
(n= 81)
PD FOG+
(n= 66)
Independent T-test ANCOVA
Control vs PD FOG− vs
FOG+
Control vs
PDa
FOG− vs
FOG+b
Global cognition
Scopa-Cog 32.00 (3.75) 28.26 (5.18) 29.38 (4.38) 26.89 (5.76) <0.001 <0.01 <0.001 0.016
Executive function/attention
SRT (m/sec) 315.69 (27.07) 342.23 (52.89) 339.98 (50.56) 345.06 (55.98) <0.001 0.574 <0.001 0.716
TMT B-A (sec) 11.83 (9.28) 21.45 (30.89) 15.59 (20.92) 28.53 (38.74) <0.001 0.019 0.031 0.054
Stroop color (sec) 31.62 (6.92) 35.91 (00.04) 34.19 (7.99) 37.98 (11.79) <0.001 0.028 <0.01 0.235
Stroop interference
(sec)
64.85 (16.92) 76.61 (31.78) 72.36 (26.87) 81.69 (36.37) <0.001 0.087 <0.01 0.113
Flankers 8.73 (0.39) 8.29 (0.67) 8.44 (0.45) 8.10 (0.83) <0.001 <0.01 <0.001 0.062
Go-NoGo (Accuracy) 74.24 (16.53) 68.37 (19.20) 71.06 (18.51) 64.99 (19.65) 0.02 0.063 0.036 0.199
Working memory
Dot counting (errors) 17.45 (4.22) 15.12 (4.13) 15.66 (3.97) 14.46 (4.26) <0.001 0.086 <0.001 0.301
Visuospatial function
Visuospatial
functionJoLO
12.80 (2.24) 12.11 (2.37) 12.21 (2.18) 12.00 (2.59) 0.039 0.608 0.047 0.784
aControlling for age, gender and years of education.
bControlling for age, gender, years of education and MDS-UPDRS III.
Fig. 2 Scatterplots representing cognitive function in older adults (OA), non-freezers (FOG−) and Freezers (FOG+). Cognitive
performance for a Scopa-cog, b Trail making Test B–A, c Dot counting and d JoLO.
R. Morris et al.
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impairments in this cohort of PD compared to healthy older
adults. In our analysis, we identified significant differences
between FOG+ and FOG− when we did not adjust for covariates;
however, when controlling for factors reflecting more advanced
disease progression, the differences were no longer significant.
Further analysis revealed that adjusting for disease severity
eliminated differences between FOG+ and FOG−, with these
findings corroborated by the weak association between FOG
severity and cognitive task performance. Incidence of cognitive
impairment and FOG are more likely as disease progresses1 and
therefore FOG may occur via two parallel process of increasing
motor disease severity advancing cognitive impairment (Fig. 1).
One theory underlying FOG episodes stipulates functional
decoupling between neural networks, identifying that the level
of functional connectivity between cognitive and motor areas may
trigger FOG episodes19. Therefore, connectivity may become
further impaired as disease progresses leading to FOG episodes,
independent of level of cognitive function. Furthermore, we
previously identified a loss of white matter fibers in an executive
inhibition pathway between the right SMA and right STN in PD
with FOG20. Therefore, cognition may play a role in some instances
of FOG but this may occur indirectly via disease severity
dependent on other factors.
A number of studies have also demonstrated worse cognition in
FOG across a number of domains, such as executive function and
attention10,12,13,21. However, the majority of studies contain small
sample sizes and as a result, often do not control for confounders
which may affect cognition e.g. disease severity and age. Unlike
our study, the majority of studies assess cognition ‘on’ dopami-
nergic medication5,10,11,13,14,21,22 whereas our patients were
assessed in the ‘off’ state. Medication status in PD not only
influences motor symptoms, but can also affect non-motor
symptoms, including cognition both in a positive and negative
manner23,24. The role of dopamine on cognition is complex,
evidence suggests that dopamine improves a number of cognitive
processes but in addition, overload of the dopaminergic system
may result in reduced cognitive performance for other cognitive
processes25–29. Furthermore, cognitive training for people with
FOG demonstrated significant improvement in FOG episodes
when in the ‘on’ state but not the ‘off’ state30. This suggests an
interplay between dopamine and cognition that underpins FOG.
Importantly, we compared our PD cohort to age-matched older
adults and demonstrated a similar pattern of cognitive impair-
ment to other studies in the literature. However, future studies
should assess cognition in FOG+ and FOG− in large cohorts both
on and off medication to better understand dopaminergic
influence on cognitive pathways in those who experience FOG.
Severity of FOG has previously been associated with severity of
cognitive deficit i.e. the more severe the FOG, the greater the
cognitive deficit10,12,14. However, we did not find any associations
between the severity of freezing and cognitive function either
with self-report or objective measures of FOG severity. In order to
improve the accuracy of FOG severity, we used an objective FOG
ratio to provide scores for OA, FOG− and FOG+. In our FOG+
group, there was a stronger association between FOG severity
ratio score and global cognition and working memory compared
to the FOG questionnaire score. It is possible that the objective
FOG ratio score provides a more sensitive metric of FOG severity
and may provide a useful outcome measure for future studies.
Our study had a number of strengths including a large cohort of
PD allowing for large and near equal size groups for FOG+ and
FOG−. Furthermore, we assessed a comprehensive range of
executive function and attention cognitive assessments, the
domain most noted to be different between FOG+ and FOG− in
Table 3. Partial correlations between objective FOG ratio and subjective questionnaire with cognitive domains.
Correlation with FOG Ratio Correlation with FOG Total Score
OA FOG− FOG+ OA FOG− FOG+
Global Cognition
Scopa-Cog −0.217 (0.089) 0.124 (0.325) −0.280 (0.040) N/A N/A −0.130 (0.350)
Executive function/attention
Simple reaction time −0.030 (0.817) −0.077 (0.541) 0.022 (0.877) N/A N/A 0.119 (0.390)
TMT B-A −0.160 (0.213) 0.129 (0.305) −0.017 (0.905) N/A N/A 0.216 (0.116)
Stroop color −0.068 (0.600) −0.115 (0.360) 0.027 (0.849) N/A N/A −0.033 (0.812)
Stroop interference 0.070 (0.586) 0.188 (0.133) 0.050 (0.719) N/A N/A 0.222 (0.106)
Flankers test 0.135 (0.296) 0.241 (0.053) −0.034 (0.806) N/A N/A −0.178 (0.199)
Go-NoGo 0.148 (0.251) −0.023 (0.853) −0.151 (0.276) N/A N/A −0.031 (0.823)
Working memory
Dot counting 0.067 (0.607) 0.116 (0.359) 0.252 (0.066) N/A N/A −0.110 (0.428)
Visuospatial function
JoLO 0.005 (0.971) −0.111 (0.379) 0.028 (0.842) N/A N/A 0.088 (0.525)
Presented are Pearson’s correlation coefficients and p-values (in brackets). Controlling for age, gender and years of education.
Fig. 3 The relationship between objective FOG severity and
global cognition assessed by scales for outcomes in Parkinson’s
disease-cognition (SCOPA-Cog). Higher FOG ratio denotes more
severe FOG, higher SCOPA-Cog score denotes better cognition.
R. Morris et al.
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previous work. However, our study also had a number of
limitations. First, our cognitive battery had a smaller number of
tests assessing memory and visuospatial function and therefore
our results may be biased towards frontal executive function and
attention. Second, although not necessarily a limitation, our
participants were all assessed ‘off’ medication and therefore our
results may be difficult to compare to other studies. Furthermore,
we compared our PD cohort ‘off’ medication to a group of age-
matched older adults and identified cognitive impairments were
similar to other studies in the literature.
Overall in this large study, we found no statistical differences in
cognitive outcomes between people with PD who do and do not
freeze when taking disease severity into account. Our findings
may have future implications for rehabilitation of FOG, however,
findings will need to be validated in a future cohort.
METHODS
Participants
Participants diagnosed with idiopathic PD and healthy age-matched older
adults (OA) were recruited to the study at Oregon Health and Science
University and the VA Portland Healthcare system. All PD participants were
screened by a movement disorders specialist at either Oregon Health and
Science University or the VA Portland Healthcare System. OA and PD
participants were included in the study if they were aged between 50 and
90 years old. People with PD were included in the study if they (i) were
diagnosed with idiopathic PD according to UK Brain Bank Criteria31 and (ii)
had no other neurological disorder other than PD. Participants were
excluded if they had cognitive difficulties so that they could not follow
instructions. Informed consent was gained from all participants All subjects
provided informed consent approved by the joint Institutional Review
Boards at Oregon Health & Science University (4131) and the VA Portland
Health Care System (8979).
FOG Classification
PD participants were classified as FOG+ if: (i) they answered yes to the first
question on the New Freezing of Gait Questionnaire (NFOG-Q)15 (Did you
experience any freezing of gait episodes within the last month?) after
seeing an accompanying video showing examples of FOG episodes, and/or
(ii) an episode of freezing was observed during a laboratory assessment. All
participants were assessed in the practical ‘Off’ medication state, with
medication withdrawn a minimum of 12 h prior to assessments.
Clinical assessments
Age, gender, years of education, and global cognitive function via the
Montreal Cognitive Assessment (MoCA) score32 were recorded for all
participants. To assess PD severity, disease duration in years was recorded
and motor severity was assessed using part III of the Movement Disorders
Society Unified Parkinson’s disease rating scale (MDS-UPDRS-III)33 and
Hoehn and Yahr score (H & Y)34. The severity of FOG was recorded
subjectively using the NFOG-Q and objectively using the FOG ratio
score17,18. The FOG ratio score was calculated from anterior-posterior
accelerations from wearable sensors on both ankles whilst participants
turned clockwise and counterclockwise 360 degrees for 1 minute. The ratio
of power at the freezing frequency band (3–7 Hz) over a walking frequency
band (0.5–2 Hz) was calculated for the turning trial.
Cognitive assessments
Four domains of cognition were assessed: global cognition, executive
function/attention, working memory and visuospatial. Global cognition was
assessed using the Scales for Outcomes in Parkinson’s disease-cognition
(SCOPA-COG) which is comprised of ten items assessing attention, working
memory, executive function, and visuospatial abilities35. Executive function
and attention were assessed by tests of simple reaction time (SRT), the time
to complete the Trail Making Test (TMT) Part B minus Part A, the time to
complete the Stroop color condition, the time to complete the Stroop
interference condition, the Flankers test, and the Go-NoGo test. Working
memory was assessed using the Dot Counting test from the NIH examiner
battery. Finally, visuospatial ability was assessed using the Benton’s
Judgement of line orientation (JoLO).
Statistical analysis
Differences in demographical characteristics were compared between
older adults and PD and FOG+ and FOG− using independent samples
t-tests and chi-square tests where appropriate. Differences in cognitive
performance were compared between: (i) PD and OA and (ii) FOG− and
FOG+. Comparisons were analyzed first without covariates using
independent samples t-test. Second, ANCOVA’s were used to detect
differences in cognitive performance whilst adjusting for covariates.
Covariates of age, gender, years of education and disease severity using
the MDS-UPDRS III were selected due to their association with cognitive
performance.
To determine associations between FOG severity and both self-report and
objective measures of FOG, partial correlations were used controlling for age,
gender and years of education. To control for multiple comparisons, statistical
significance was set at α< 0.01 throughout the analysis.
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding
author upon reasonable request.
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